Which symptoms are indicative of DSMIV depression in cancer settings? An analysis of the diagnostic significance of somatic and non-somatic symptoms

Mitchell, Alex J.; Lord, Karen; Symonds, Paul

doi:10.1016/j.jad.2011.11.009

Cited by 54 publications

(59 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Eventhough HADS seems to detect about similar prevalence of depression as compared to the diagnostic tools, it is not recommended to be used for case-finding instrument but suitable in screening programme (Mitchel et al, 2010). Analysis of the items in HADS-depression used in cancer patients, combination of "feeling down, depressed or hopeless" with "thoughts that would be better off dead, little interest or pleasure in doing things" gave high sensitivity but low specificity (Mitchell et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

Prevalence of Depression in Breast Cancer Survivors: a Systematic Review of Observational Studies

Zainal¹,

Nik-Jaafar²,

Baharudin³

et al. 2013

Asian Pacific Journal of Cancer Prevention

159

115

View full text Add to dashboard Cite

Background: Depression is common in breast cancer patients. The aim of this paper was to make a systematic review of its prevalence and associated factors oin breast cancer survivors. Materials and Methods: An extensive systematic electronic review (PUBMED, CINAHL, PsyINFO and Ovid) and handsearch were carried out to retrieve published articles up to November 2012, using Depression OR Dysthymia AND (Cancer OR Tumor OR Neoplasms as the keywords. Information about the design of the studies, measuring scale, characteristics of the participants, prevalence of depression and its associated factors from the included studies were extracted and summarized. Results: We identified 32 eligible studies that recruited 10,826 breast cancer survivors. Most were cross-sectional or prospective designed. The most frequent instrument used to screen depression was the Center for Epidemiological Studies for Depression (CES-D, n=11 studies) followed by the Beck Depression Inventory (BDI, n=6 studies) and the Hospital Anxiety and Depression Scale (HADS, n=6 studies). CES-D returned about similar prevalence of depression (median=22%, range=13-56%) with BDI (median=22%, range=17-48%) but higher than HADS (median=10%, range=1-22%). Depression was associated with several socio-demographic variables, cancer-related factors, treatment-related factors, subject psychological factors, lifestyle factors, social support and quality of life. Conclusions: Breast cancer survivors are at risk for depression so that detection of associated factors is important in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of Depression in Breast Cancer Survivors: a Systematic Review of Observational Studies

Zainal¹,

Nik-Jaafar²,

Baharudin³

et al. 2013

Asian Pacific Journal of Cancer Prevention

159

115

View full text Add to dashboard Cite

show abstract

“…Suggestions have been made to remove (Bukberg et al, 1984;Rayner et al, 2011a;Zimmerman et al, 2006) or to substitute (Endicott, 1984) the somatic depression symptoms when assessing depression in the medically ill. Others have argued for the retention of the somatic symptoms as they can be diagnostically useful (Mitchell et al, 2012a;van Wilgen et al, 2006) and seem to have little effect on prevalence rates, at least when levels of depressive symptoms are high (Chochinov et al, 1994;Kathol et al, 1990;Mitchell et al, 2012a;van Wilgen et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

“…Yet, the potential effect of somatic disease load on detecting depression in cancer patients is rarely considered (Chen and Chang, 2004;Mitchell et al, 2012a;Rayner et al, 2011a;Rodin et al, 2009;Smith et al, 2003;Teunissen et al, 2007b). A recent review demonstrated that core medical characteristics were unsystematically and inconsistently described in studies of depression in patients with advanced cancer (Janberidze et al, 2014b).…”

Section: Introductionmentioning

confidence: 99%

Depression in advanced cancer – Assessment challenges and associations with disease load

Lie

Hjermstad

Fayers

et al. 2015

Journal of Affective Disorders

View full text Add to dashboard Cite

“…The PHQ-9 was selected based on its wide use in medical populations (Manea, Gilbody, & McMillan, 2012), established severity ranges and sensitivity to change , specific recommendation in guidelines for management of depression in cancer patients (Andersen et al, 2014) and inclusion of somatic symptoms, which are recognised as a core domain of depression, not confounding diagnosis in cancer survivors (Mitchell, Lord, & Symonds, 2012). In non-cancer populations, scores from 10 to 14 indicate mild-moderate depression; 15-19 moderately severe (Kroenke et al, 2001).…”

Section: Effectiveness Outcomesmentioning

confidence: 99%

Phase II trial of a depression self-care intervention for adult cancer survivors

et al. 2017

View full text Add to dashboard Cite

Supported self-care interventions are a low-intensity treatment for depression that has received little research attention in the cancer population. This is a phase II intervention only study to test the feasibility, acceptability and preliminary effectiveness of a depression self-care intervention for cancer patients who have completed their primary treatment and have moderate depressive symptoms. The self-care intervention was adapted from a successful model for people with chronic physical conditions, following focus groups with cancer care professionals and patients. The support was delivered by telephone by a trained lay coach who provided up to 8 weekly coaching contacts. A variety of recruitment methods were tested; those with the highest yield of eligible subjects per research staff time were electronic mailings to community support group members and social media posting. Sixty-eight people were contacted about the study over an 11-month period, of whom 34 (49%) were eligible; 32 were enrolled (94% recruitment rate); and 25 completed 2-month follow-up (78% retention). The mean severity of PHQ-9 depression decreased significantly from screening to 2 months (12.8 to 7.0, p < .0001). The intervention is a promising treatment option for cancer survivors, demonstrating sufficient effectiveness and feasibility to proceed with a phase III clinical trial. K E Y W O R D Scancer survivorship, depression, feasibility, intervention, self-care, self-management

show abstract

Which symptoms are indicative of DSMIV depression in cancer settings? An analysis of the diagnostic significance of somatic and non-somatic symptoms

Cited by 54 publications

References 36 publications

Prevalence of Depression in Breast Cancer Survivors: a Systematic Review of Observational Studies

Prevalence of Depression in Breast Cancer Survivors: a Systematic Review of Observational Studies

Depression in advanced cancer – Assessment challenges and associations with disease load

Phase II trial of a depression self-care intervention for adult cancer survivors

Contact Info

Product

Resources

About